<SEC-DOCUMENT>0001564590-21-033742.txt : 20210622
<SEC-HEADER>0001564590-21-033742.hdr.sgml : 20210622
<ACCEPTANCE-DATETIME>20210622094657
ACCESSION NUMBER:		0001564590-21-033742
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210622
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210622
DATE AS OF CHANGE:		20210622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JanOne Inc.
		CENTRAL INDEX KEY:			0000862861
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-HOME FURNITURE, FURNISHINGS & EQUIPMENT STORES [5700]
		IRS NUMBER:				411454591
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19621
		FILM NUMBER:		211033292

	BUSINESS ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119
		BUSINESS PHONE:		702-997-5968

	MAIL ADDRESS:	
		STREET 1:		325 E. WARM SPRINGS ROAD
		STREET 2:		SUITE 102
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	APPLIANCE RECYCLING CENTERS OF AMERICA INC /MN
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>jan-8k_20210622.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
jan-8k_20210622.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-top:Double 2.25pt;padding-top:1pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /><font style="font-size:12pt;">WASHINGTON, D.C. 20549</font></p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): June 22, 2021</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JANONE&#160;INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Charter)</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:9pt;line-height:4pt;margin-bottom:0pt;margin-right:41.28%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nevada</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">000-19621</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">41-1454591</p></td>
</tr>
<tr>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top"  style="width:34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification&#160;No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">325 E. Warm Springs Road, Suite 102</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Las Vegas, NV 89119</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices and Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: 702-997-5968</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:41.28%;margin-right:41.28%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:35%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:43%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.001 par value per share</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JAN</p></td>
<td valign="bottom"  style="padding-left:10pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-10pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:43%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The NASDAQ Stock Market LLC </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(The NASDAQ Capital Market)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01<font style="font-weight:normal;">&#160;</font>Other Events.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.88%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 22, 2021, JanOne Inc. issued a press release announcing the selection of Avania as its regulatory partner in the upcoming Phase 2b trial of lead product candidate JAN101 for treating Peripheral Artery Disease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.88%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.88%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.68%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) &#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:89%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:89%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="jan-ex991_14.htm"><font style="text-decoration:none;">Press Release of JanOne Inc., dated June 22, 2021</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SIGNATURES</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.68%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:35%;">
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JanOne Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:89.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Tony Isaac </p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&#160;&#160;Tony Isaac</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&#160;&#160;&#160;&#160;Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated:&nbsp;&nbsp;June 22, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>jan-ex991_14.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
jan-ex991_14.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="g3ziodjdtqxa000001.jpg" title="" alt="" style="width:261px;height:73px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:12pt;text-transform:none;font-variant: normal;">Global Contract Research Organization (CRO) Avania to Manage All Regulatory Affairs in Connection with JanOne&#8217;s Phase 2b Trial Preparedness and Execution</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LAS VEGAS,&#160;June 22, 2021&#160;/PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced its selection of <font style="text-decoration:underline;">Avania</font> as its regulatory partner in the upcoming planned Phase 2b trial of lead product candidate JAN101 for treating Peripheral Artery Disease (PAD). Avania will manage all regulatory operations associated with trial preparedness and execution including ensuring compliance with the FDA&#8217;s requirements for investigational practices and managing correspondence with the FDA on JanOne&#8217;s behalf throughout the duration of the trial.  Avania has recently completed the filing of the annual report for IND 111703 on behalf of JanOne.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tony Isaac, President and Chief Executive Officer of JanOne, commented, &#8220;We are pleased with our selection of Avania as our regulatory partner for our upcoming planned Phase 2b trial and will rely on their globally recognized expertise as we prepare to first file our pre-Phase 2 briefing package this summer and, following our planned meeting with the FDA, file our new protocol and related documents. Avania will assist us through each aspect of filing, including the clinical protocol, the Investigator's Brochure (IB), the General Investigational Plan, and Chemistry, Manufacturing, and Control (CMC) updates. We have made great progress year-to-date as we approach our protocol filing, and once approved by the FDA, we look forward to the expected initial recruitment of PAD subjects for this important trial.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Avania is an integrated global, full-service contract research organization (CRO) with specialized expertise in medical device, novel technology, and combination products. Avania advances products from feasibility all the way through post-approval trials in analytics, clinical trials, consulting, regulatory, and reimbursement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JanOne recently announced its completion of Current Good Manufacturing Practices (CGMP) production of the first batch of JAN101, an initial step along the path to initiation of the Phase 2b PAD trial.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">About JanOne</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk68639173"></a>JanOne (Nasdaq: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-addictive pain medications. Its lead candidate</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> JAN101</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is for </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potentially </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treating peripheral artery disease (</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PAD</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase&#160;2b&#160;trials are expected to begin </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the near future</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. JanOne is dedicated to funding resources toward innovation, technology</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and education for PAD, associated vascular conditions</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk68639173"></a> and neuropathic pain. </font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information, visit&#160;</font><font style="text-decoration:underline;">www.</font><font style="text-decoration:underline;">janone.com</font><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking and Cautionary Statements</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, including statements relating to the upcoming Phase 2b trials, and filing of the pre-Phase 2 briefing package and planned meeting with the FDA. These forward-looking statements can be identified by terminology such as &#8220;will,&#8221; &#8220;aims,&#8221; &#8220;upcoming,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;expected,&#8221; &#8220;potential,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates&#8221; and similar statements. JanOne may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on Forms 10-K and 10-Q, Current Reports on Form 8-K, in its annual report to stockholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report on Form 10-K for the fiscal year ended&#160;January 2, 2021&#160;and other SEC filings (available at&#160;http://www.sec.gov). JanOne undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations &amp; Media Contact<br /><font style="font-weight:normal;">IR@Janone.com<br />1 (800) 400-2247</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g3ziodjdtqxa000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g3ziodjdtqxa000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "" = # 2(  A$! Q$!_\0
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MR&65Y&^\[%C^-?4-?,=[ ;6^N+<C!BE9"/H<5OBNAX?"S5ZJ]/U(*^C_  W
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M=_QZVW^^?Y5]GFO^YS_KJCY[!?[Q$Y*NA\)?\A"?_KE_45SU=#X2_P"0A/\
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MJO\ LS,/Y7]Z_P R?KF%[_@_\CEZM::YCU2U;TE7/YUO?\(?_P!/_P#Y!_\
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M2-6"Y![\GM_6@!WQ$1SIMFXSY:RD-]2./Y&M7P?-#+X9M!"1^[!1P.S9)/\
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<#5HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
